AbbVie Inc (ABBV) : Marble Harbor Investment Counsel reduced its stake in AbbVie Inc by 0.85% during the most recent quarter end. The investment management company now holds a total of 202,198 shares of AbbVie Inc which is valued at $13,537,156 after selling 1,729 shares in AbbVie Inc , the firm said in a disclosure report filed with the SEC on Aug 8, 2016.AbbVie Inc makes up approximately 3.25% of Marble Harbor Investment Counsel’s portfolio.
Other Hedge Funds, Including , Schooner Investment Group. reduced its stake in ABBV by selling 2,500 shares or 33.33% in the most recent quarter. The Hedge Fund company now holds 5,000 shares of ABBV which is valued at $334,750. AbbVie Inc makes up approx 0.79% of Schooner Investment Group.’s portfolio.Keating Investment Counselors Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 3,000 additional shares and now holds a total of 6,843 shares of AbbVie Inc which is valued at $455,539. AbbVie Inc makes up approx 0.22% of Keating Investment Counselors Inc’s portfolio.Lee Danner Bass Inc boosted its stake in ABBV in the latest quarter, The investment management firm added 400 additional shares and now holds a total of 14,276 shares of AbbVie Inc which is valued at $950,353. AbbVie Inc makes up approx 0.12% of Lee Danner Bass Inc’s portfolio.Starfire Investment Advisers boosted its stake in ABBV in the latest quarter, The investment management firm added 6 additional shares and now holds a total of 4,157 shares of AbbVie Inc which is valued at $275,318. AbbVie Inc makes up approx 0.18% of Starfire Investment Advisers’s portfolio.Evanson Asset Management reduced its stake in ABBV by selling 171 shares or 1.73% in the most recent quarter. The Hedge Fund company now holds 9,692 shares of ABBV which is valued at $614,570. AbbVie Inc makes up approx 0.18% of Evanson Asset Management’s portfolio.
AbbVie Inc opened for trading at $67.47 and hit $68.1239 on the upside on Monday, eventually ending the session at $67.39, with a gain of 0.30% or 0.2 points. The heightened volatility saw the trading volume jump to 52,15,360 shares. Company has a market cap of $109,747 M.
On the company’s financial health, AbbVie Inc reported $1.26 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 29, 2016. Analyst had a consensus of $1.20. The company had revenue of $6452.00 million for the quarter, compared to analysts expectations of $6207.43 million. The company’s revenue was up 17.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.08 EPS.
Many Wall Street Analysts have commented on AbbVie Inc. AbbVie Inc was Downgraded by Morgan Stanley to ” Equal-Weight” on Jun 8, 2016.
AbbVie Inc. (AbbVie) is a global research-based biopharmaceutical company. The Company develops and markets therapies that address a range of diseases. The Company’s products are focused on treating conditions such as chronic autoimmune diseases including rheumatoid arthritis psoriasis and Crohn’s disease; hepatitis C (HCV); human immunodeficiency virus (HIV); endometriosis; thyroid disease; Parkinson’s disease; complications associated with chronic kidney disease and cystic fibrosis and other health conditions such as low testosterone. AbbVie also has a pipeline of new medicines including over 30 compounds or indications in Phase II or Phase III development across a range of medical specialties such as immunology virology/liver disease oncology renal disease neurological diseases and women’s health. The Company’s product portfolio includes HUMIRA HCV products Additional Virology products Metabolics/Hormones products Endocrinology products and other products.